JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease
Juan Li(University of Cambridge), Anthony R. Green(Wellcome/MRC Cambridge Stem Cell Institute), David G. Kent(University of York), Cédric Ghevaert(NHS Blood and Transplant), Kourosh Saeb‐Parsy(University of Cambridge), Harriet Manning(National Health Service), Rachel Sneade(Wellcome/MRC Cambridge Stem Cell Institute), Yvonne Silber(University of Namur), Tina L. Hamilton(Wellcome/MRC Cambridge Stem Cell Institute), Edwin Chen(University of Cambridge), Xiaodong Zhao(Wellcome/MRC Cambridge Stem Cell Institute), Dean C. Pask(Wellcome/MRC Cambridge Stem Cell Institute), Jyoti Nangalia(Wellcome Sanger Institute), Athar Aziz(Wellcome/MRC Cambridge Stem Cell Institute), Pentao Liu(Hong Kong Science and Technology Parks Corporation), Juergen Fink(Wellcome/MRC Cambridge Stem Cell Institute), Anna L. Godfrey(University of Namur)
Cited by 90
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Cells of the adult human heart
|Nature|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k